The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, open-label study in China.
 
Jian Li
No Relationships to Disclose
 
Jun Zhang
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Haibo Qiu
No Relationships to Disclose
 
Yanbing Zhou
No Relationships to Disclose
 
Yongjian Zhou
No Relationships to Disclose
 
Xinhua Zhang
No Relationships to Disclose
 
Ye Zhou
No Relationships to Disclose
 
Yuping Zhu
No Relationships to Disclose
 
Yong Li
No Relationships to Disclose
 
Ming Wang
No Relationships to Disclose
 
Kuntang Shen
No Relationships to Disclose
 
Kaixiong Tao
No Relationships to Disclose
 
Xin Wu
No Relationships to Disclose
 
Haijiang Wang
No Relationships to Disclose
 
Bo Zhang
No Relationships to Disclose
 
Jiayu Ling
No Relationships to Disclose
 
Yingjiang Ye
No Relationships to Disclose
 
Juan Dong
Employment - Zai Lab
Stock and Other Ownership Interests - Zai Lab
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche
Speakers' Bureau - Hutchison Whampoa; MSD
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)